melanoma tumor homogenate vaccine

Melanoma tumor homogenate vaccine is an autologous cancer vaccine platform that utilizes processed tumor tissue (homogenate) from a patient's own melanoma as a source of tumor-associated antigens. This approach aims to stimulate a personalized anti-tumor immune response. In some clinical applications, the tumor homogenate is loaded onto dendritic cells to enhance antigen presentation to T-cells, while other versions use the subcellular homogenate directly without adjuvants. Research has primarily focused on treating patients with Stage I-IV melanoma, with Phase II trials demonstrating the potential to induce tumor-specific immune responses and improve survival in high-risk populations. It is often evaluated as a monotherapy or in combination with immunomodulators like interferon-alpha.

Other names

autologous melanoma tumor homogenate vaccinedendritic cell-based melanoma tumor homogenate vaccinesubcellular melanoma tumor homogenate vaccine